References 1.Roach P.J., Depaoli-Roach A.A., Hurley T.D., Tagliabracci V.S
3.3.4 Polyethylene glycol loxenatide The early GLP-1R agonist has many defects, such as multiple injections and a high incidence of adverse reactions in the digestive tract, which limits its clinical application
"With 7 additional phase 3 readouts expected in 2026..." -- Kenneth Custer, PhD, EVP Lilly Cardiometabolic Health TRIUMPH-1 -- Obesity -- RESULTS (May 2026) TRIUMPH-1 is the pivotal general-obesity trial that forms the basis of Lilly's weight-management regulatory submission
Furthermore, the Canadian Community Health Survey (CCHS) reported that 30% of adult Canadians were obese in 2022
Hinojosa recommends: Gradual dose increases as prescribed Slower, steady weight loss (around 1 pound per week) Regular meals with a balanced diet Avoiding extreme low-fat or very high-fat diets You dont need to avoid fat completely, but you also dont want to eat an extremely high-fat diet, he says
N Engl J Med 391:109121